Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT06586255
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Concurrent Immunotherapy and Radiation Therapy — RADIATION
    Radiation therapy will begin between 12 to 18 weeks from the start of adjuvant nivolumab. Patients will receive radiation therapy for about 6 weeks.

Study Details

The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.

Key Dates

Start date
Apr 29, 2025
Status verified
May 2026
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Concurrent Immunotherapy and Radiation Therapy
    Subjects will receive the standard of care procedures and follow-up for immunotherapy and radiation therapy. The part of this study that is research is receiving both of these treatments at the same time.

Primary Outcome Measure

Safety of concurrent adjuvant immunotherapy and radiation therapy [ Time Frame: Within 18 weeks from start of radiation therapy ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of PennsylvaniaPhiladelphiaPennsylvania19104
Project Manager
[email protected]
215-662-3790
John Christodouleas, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By condition
Bladder cancer
By specialty
OncologyUrology
By research site
University of Pennsylvania· Philadelphia, PA

Related Studies